Abstract Purpose: Fractionated radioimmunotherapy may improve therapeutic outcome by decreasing heterogeneity of the dose delivered to the tumor and by decreasing hematologic toxicity, thereby allowing an increased amount of radionuclide to be administered. Because humanized anti-CD22 epratuzumab can be given repeatedly, a single-center study was conducted to establish the feasibility, safety, optimal dosing, and preliminary efficacy of weekly administrations of ]epratuzumab achieved a high objective response rate (62%) across lymphoma subtypes, including durable CRs. The findings that three weekly infusions (555 MBq/m 2 , total dose) can be administered safely with only minor toxicity, that antibody levels increased during treatment weeks, and that therapeutic response predominantly occurs in patients with unequivocal CD22 tumor expression provide guidance for future studies.
I]tositumomab (Bexxar, Glaxo SmithKline, Philadelphia, PA) was subsequently approved for the treatment of patients with CD20-positive, follicular NHL, with and without transformation, whose disease is refractory to rituximab and has relapsed following chemotherapy (5 -9) . In both regimens, the therapeutic dose is delivered as a single administration. There are, however, compelling arguments for a fractionated schedule of dose delivery, because fractionation would better deal with the problem of heterogeneity in absorbed dose, as well as decreasing hematologic toxicity, thereby allowing increased amount of radionuclide to be administered (10, 11) . There are also experimental data indicating that therapeutic response can be improved by splitting a large single dose of radiolabeled antibody into a number of smaller administrations (12) . Further, both approved radioconjugates involve labeled murine antibodies. The [ 90 Y]ibritumomab tiuxetan regimen also requires two additional 250 mg/m 2 infusions of chimeric rituximab, whereas the [ 131 I]tositumomab regimen also requires two additional 450 mg infusions of unlabeled murine tositumomab. Although radioimmunotherapy approaches with two or more infusions have been explored clinically using murine antibodies in B-cell malignancies (13, 14) , immunogenicity might limit the potential for continued application, and there have been no reports of fractionated studies extending these treatment regimens.
Epratuzumab is a humanized antibody in which the parent antibody has been replaced with f90% human IgG1 sequences and the only remaining murine immunoglobulin sequences restricted to the complementarity-determining regions of the binding site (15) . As such, epratuzumab is not expected to evoke human anti-human antibodies (HAHA), which makes it suitable for repeated dosing. Epratuzumab binds specifically to the third immunoglobulin domain of CD22, a B-cell -restricted, lineage-dependent antigen that is rapidly internalized upon antibody binding (16, 17) . CD22 seems to be involved in the regulation of B-cell activation as well as cell adhesion (18) and in vitro studies of epratuzumab with normal as well as neoplastic B cells support the ability to stimulate internalization as well as promote CD22 signaling (19) . Epratuzumab has shown efficacy and safety in clinical studies of B-cell malignancies (20, 21) , including retreatment (22) and when administered in combination with rituximab (23) .
Although the mouse parental antibody (mLL2) labeled with 131 I has shown efficacy in various subtypes of B-cell lymphoma (14, 24) , after internalization the 131 I-labeled antibody is dehalogenated and the radionuclide is released from the cell. Subsequent radioimmunotherapy trials with epratuzumab used 90 Y, a residualizing radiometal that is retained in the cell upon internalization (25) and distributes h emission over a longer tissue range than 131 I, thus potentially extending therapeutic efficacy in regions of poorly vascularized tumor. For radiolabeling, epratuzumab was conjugated with the macrocyclic chelating agent 1,4,7,10-tetra-azacyclodecane-N,NV ,NV V ,NV V V-tetraacetic acid (DOTA), and binding studies of DOTA-conjugated epratuzumab labeled with 90 
Materials and Methods
This single-center, open-label, dose-escalation, phase I/II study evaluated the feasibility, safety, optimal dosing, and preliminary efficacy of [ 90 Y]epratuzumab administered once weekly for an increasing number of 2 to 4 consecutive weekly infusions (Fig. 1) In]epratuzumab following the first infusion. They had adequate performance status (Karnofsky z70%, or Eastern Cooperative Oncology Group 0-2) with a minimal life expectancy of 3 months; were z4 weeks beyond any prior chemotherapy, any major surgery, or any radiation therapy to the index lesion; z2 weeks beyond change in dosage of corticosteroids; and patients who received an investigational agent must have completed follow-up and be off-study. Required laboratories were as follows: serum creatinine V1.5 mg/dL (or creatinine clearance z50 mL/min), bilirubin V2 mg/dL, WBC z3,000/mm 3 , granulocytes z1,500/mm 3 , and platelets z100,000/mm 3 . Exclusion criteria included central nervous system lymphomatous involvement, z25% B cells in unseparated bone marrow by flow cytometry, radiation to specific organs or areas at the maximum tolerated level or to >25% red marrow, splenomegaly, pregnancy, and premenopausal women unwilling to practice adequate birth control.
Both DOTA-conjugated epratuzumab and unconjugated epratuzumab were supplied by Immunomedics, Inc. (Morris Plains, NJ). DOTAepratuzumab was supplied in 12.0 mg vials (10 mg/mL) for radiolabeling with either InCl 3 (Mallinckrodt Medical B.V., Petten, the Netherlands) according to procedures described by Griffiths et al. (26) . After a 15-minute incubation at 45jC, diethylenetriaminepentaacetic acid was added to quench the reaction and bind any remaining free isotope. Patient administration required at least 85% of the isotope must be antibody bound, and binding results for the radiolabeling procedure were determined by instant thin-layer chromatography to be 92. 90 Y standard with injected activity determined by the difference in syringe measurement before and after injection, whereas 150 MBq (4 mCi) [ 111 In]epratuzumab was used when imaging was done. Radiolabeled epratuzumab was diluted in 10 mL sterile saline containing 1% human serum albumin, and unlabeled epratuzumab added to achieve a total antibody dose of 1.5 mg/kg. After f10% of the dose was infused i.v., with no significant reaction and stable vital signs, the infusion was to be completed over f30 minutes.
Toxicity was scored according to the National Cancer Institute Common Toxicity Criteria, version 2.0. Dose-limiting toxicity was defined as hematologic toxicity grade 3 lasting >28 days or grade 4 >14 days, whereas any grade 3 nonhematologic toxicity of any duration was regarded as dose-limiting toxicity. For dose escalation, patients were entered in dose cohorts of three to six patients, with the first cohort receiving 2 consecutive weekly infusions, the second cohort 3 weeks, and the third 4 weeks. If three patients in a cohort did not encounter dose-limiting toxicity, dose escalation was to proceed, but if one patient encountered dose-limiting toxicity, the cohort was to be expanded up to six patients, with escalation proceeding only if no additional patient encountered dose-limiting toxicity.
Baseline investigations were done within 4 weeks of initiating treatment and included physical examination; computed tomography scans of the thorax, abdomen, and pelvis; bone marrow biopsy; routine laboratories; and a blood sample for determination of HAHAs. During the 12 weeks posttreatment evaluation period, blood samples for hematology were obtained at least weekly and increased to twice to thrice per week in the event of grade 3 toxicity; serum chemistries were obtained at 1 and 4 weeks; blood samples for HAHA at 2, 4, 8, and 12 weeks; and physical examinations at 4 and 12 weeks. Evaluation of treatment response after the last weekly infusion included clinical examination and computed tomography scans at 4 to 6 weeks and 12 weeks and thereafter at least every 3 months until recurrence. Bone marrow biopsy was repeated if bone marrow had been involved previously. The treatment could be repeated once after 3 months provided there was neither severe toxicity nor progression of the disease.
The first infusion also included [ 111 In]epratuzumab. Blood samples for pharmacokinetics and calculation of bone marrow absorbed dose (29) were to be obtained at 5 minutes after the first weekly infusion, then at 1 hour; 2 to 4 hours; 1, 2, and 3 to 5 days; and at 7 days. In addition to counting 111 In and 90 Y serum radioactivity, serum samples were shipped to Immunomedics for determination of antibody levels using an ELISA assay. Scintigraphic imaging for tumor targeting and dosimetry was done following the first infusion, then at 1, 2, 3 to 5, and 6 to 7 days. Imaging sessions included anterior and posterior wholebody images as well as planar views of the head/neck, chest, abdomen, and pelvis, with at least one single-photon emission computed tomography session including regions of suspected or confirmed tumor masses. The conjugate view method was used for activity quantification (30) . Anterior and posterior regions of interest were drawn around organs and tumors, and activity calculated from the geometric mean of region of interest counts. After correcting for background, attenuation, and camera sensitivity,
111
In activity was converted to 90 Y activity by correcting for differences in physical decay. Using a monoexponential or biexponential curve fit to organ time-activity, the total cumulated activity was calculated as the area under the curve extrapolated to infinite time. Organ and tumor absorbed doses (the cumulated activity times the S value) were calculated using medical internal radiation dose formulas (31) .
Tumor responses were assessed by International Workshop criteria (32) as CR (complete disappearance of all disease-related radiologic abnormalities and other assessable disease), CRu (one or more residual tumors >1.5 cm in diameter that regressed by >75% in the sum of the products of the two longest perpendicular diameters, SPD), partial response (50% or greater reduction in SPD of the six largest measurable sites, and no new lesions), progressive disease (>25% increase from the nadir value in the SPD of measurable lesions or the appearance of a new lesion), or stable disease (<50% reduction or <25% increase from the nadir in the SPD of measurable lesions, with no new lesions). An objective response is either a complete response (CR/Cru) or partial response with duration measured from onset of objective response to progressive disease. Intervals measured in all patients include time to progression (start of treatment to progression or death), event-free survival (start of treatment to death from any cause or failure in patients with an objective response), or time-to-treatment failure (start of treatment to death, progression, or change in therapy from any cause).
CD22 expression levels on lymphoma cells isolated from selected biopsy, bone marrow, or blood specimens were assessed by flow cytometry using FITC-labeled anti-CD22 monoclonal antibody M0738 (clone 4KB128; DAKO, Copenhagen, Denmark), which binds domain 2 of CD22 without interference from epratuzumab. CD22 expression was analyzed by quadrant analysis and described in a semiquantitative manner (Fig. 2) . Negative expression was defined using the non -B cells among the analyzed cells. CD22 expression was described as ''definitely positive'' when virtually all tumor cells were positive, as ''weakly positive'' when more than a few percentage of the cells were not clearly positive, and as ''negative'' when less than a few percentage or no cells were positive.
Results
Patient characteristics and responses. Patient characteristics for the 16 patients treated in this study are summarized in Table 1 . Initially, three patients were treated at dose level 1 (2 consecutive weekly doses) and three patients at dose level 2 (3 consecutive weekly doses) without more than grade 2 toxicity. After treatment was advanced to dose level 3 (4 consecutively weekly doses), two patients experienced dose-limiting toxicity and the remaining five patients were then studied at dose level 2.
Treatment response data are given for each of the 16 patients in Table 2 . Ten patients (62%; 95% confidence interval, 39-86%) had an objective response, including four (25%) with CR/ CRu. For these 10 patients, the time to best treatment response was 6 to 22 weeks (median 8 weeks) and the median event-free survival was 7 months (26 months for the four patients with CR/ CRu). Objective responses occurred in five of the six patients with indolent follicular lymphoma, with the other patient found to have a transformed lymphoma at a posttreatment biopsy, and each of the five other objective responses involved other lymphoma histologies: aggressive (i.e., grade 3) follicular, transformed follicular, mantle cell, mucosa-associated lymphoid tissue, and diffuse large B-cell lymphoma. Objective responses (all partial responses) occurred for four of seven patients with at least one tumor >5 cm in one dimension, both patients with a tumor burden >500 g, and two patients with pleural effusion (with resolution of the effusion in one patient). Table 2 compares best response to last treatment with response data after radioimmunotherapy: Two of four patients with progressive disease achieved objective responses with radioimmunotherapy (including one CR), one of three patients with stable disease achieved a partial response with radioimmunotherapy, four of five patients with partial responses achieved objective responses with radioimmunotherapy (including one CR), and both patients with complete responses (CR or CRu) again had complete responses after radioimmunotherapy. For eight patients, the time-to-treatment failure after radioimmunotherapy was longer than it was following prior treatment. Among the seven patients with response data also available after previous rituximab treatment, all seven patients showed comparable or better response with radioimmunotherapy, including partial responses in two of four patients without any prior objective response to rituximab, and CRs in two of three patients with partial responses after rituximab.
CD22 expression. Lymphoma cells were evaluated by flow cytometry in 13 patients (10 from tumor masses, 2 from involved bone marrow, and 1 from blood). Objective responses occurred in seven of eight patients with definitely positive CD22 expression (including three CRs) and one of four patients with weakly CD22-positive tumor cells who had partial response, whereas the only patient with CD22-negative tumor cells exhibited progressive disease. Thus, response rates seem to be strongly correlated with unequivocal CD22 tumor expression (seven of eight versus one of five, P = 0.032 by Fischer's exact test).
Tumor (Table 3) . Estimates of median cumulative radiation doses in patients treated at each dose level can then be obtained by multiplying the tabulated values by the number of infusions administered. Although such an approach necessarily ignores possible pharmacokinetic and biodistribution changes that may occur with subsequent infusions, the resulting cumulative radiation dose estimates in this study are seen to remain below generally accepted limits of 3 Gy to the red marrow for nonmyeloablative therapy and 20 Gy to the liver, lungs, and kidneys. Fifteen patients showed unequivocal tumor uptake, whereas one patient had equivocal uptake in spite of a CD22-positive tumor. Twelve patients with targeting and adequately determined tumor volumes also had tumor dosimetry estimates calculated from a single 185 MBq/m 2 [ 90 Y]epratuzumab administration (Table 3) . Median tumor doses for the first fractionated injections were 5.8 Gy (5.7-9.6) for three patients with CRs, compared with 2.2 Gy (1.2-4) for five patients with partial responses and 4.2 Gy (0.9-6.8) for four nonresponders, and 4.6 Gy (2.1-9.6) for seven patients with definitely positive CD22 expression, compared with 3.9 Gy (0.9-6.8) for three patients with weakly positive tumors and 3.6 Gy for the single patient with negative expression.
Toxicity. The only significant toxicity was hematologic, but no patient received either hematopoietic growth factors or platelet transfusions. No patient had any bleeding episode and no patient had a significant infection, except one who developed a Pneumocystis carinii infection, which responded to treatment with trimethoprim-sulfamethoxazole. As summarized in Table 4 , for the 10 patients treated at dose levels 1 and 2 (i.e., with 2-3 consecutive weekly doses), eight patients had grade 0 to 2 hematologic toxicity and two patients had grade 3 neutropenia. Median time for recovery was week 9 after treatment. Of five patients at dose level 3, two had doselimiting hematologic toxicity (grade 4 toxicity for 5 weeks, grade 3 for >7 weeks); both patients had received cytosar (3 g/m 2 , twice daily for 2 days) as their last chemotherapy infusion within 2 months of the start of radioimmunotherapy.
Excluding one patient who received concomitant chemotherapy (MIME) and another with rapidly falling platelets probably due to progressive disease, linear regression of a patient's maximum hematologic toxicity grade with the number of 185 MBq/m 2 infusions received (i.e., dose level) resulted in a correlation of R 2 = 0.43 (P = 0.01 by Jonckheere-Terpstra test). Fifteen patients had least one posttreatment serum sample evaluated for HAHA, including 13 patients with samples within 4 weeks, nine patients with samples at 8-week evaluations, and 12 patients with 12-week samples. No patients developed HAHA.
Pharmacokinetics. Epratuzumab peak and trough serum levels were measured immediately preceding and 2 hours Table 5 , levels increased with each 1.5 mg/kg infusion, with a mean C max of 65.4 Ag/mL after fourth infusion. In the initial 12 patients, serum samples collected over the week following the first and last infusions were fit with a monoexponential function to determine circulation half-lives. As seen, mean half-lives increased from f4.5 days after the first infusion to f14 days after the fourth infusion.
Retreatment 111 In]epratuzumab administered at the third infusion, which showed a lower tumor uptake (2.0 Gy) compared with the first infusion (4.5 Gy). None of these four patients had more than grade 2 hematologic toxicity or evidence of cumulative toxicity. Three patients had samples evaluated for HAHA following retreatment and none was positive.
Discussion
Patients in this study received 2 to 4 weekly administrations of 185 MBq/m 2 [ 90 Y]epratuzumab coinfused with unconjugated epratuzumab at a 1.5 mg/kg/wk total protein dose. This fractionated schedule of radioimmunotherapy was well tolerated with only minor infusional reactions. Hematologic toxicity was moderate and dose-limiting hematologic toxicity was not encountered until patients received 4 weekly doses. Dosimetry estimates from the first infusions showed that radiation doses Of the 16 patients, 62% achieved an objective response, including patients with aggressive as well as indolent disease, and with large (>500 mL) tumor burdens. In addition, 25% of patients achieved complete responses (CR/CRu) and these patients had particularly durable responses (event-free survival, 14-41 months). The 62% response rate compares favorably with the 50% response rate to the preceding therapy, and 50% of all patients had longer time-to-treatment failure following radioimmunotherapy than after their previous treatment. Although this was a dose-escalation study enrolling small numbers of patients across various indolent and aggressive histologies, these response rates seem comparable with those obtained in the pivotal trials of [ 90 Y]ibritumomab tiuxetan (80% objective response, 34% CR/CRu) or [
131 I]tositumomab (65% objective response, 20% CR), both of which were restricted to patients with more favorable histologies (i.e., predominantly indolent follicular lymphoma; refs. 3, 7). In addition to lymphoma subtype, prior therapies may also influence radioimmunotherapy responsiveness, as supported by a recently reported trial demonstrating the ability of radioimmunotherapy administered as initial therapy to induce a superior response rate and prolonged clinical and molecular remissions in patients with advanced follicular lymphoma (33) .
A major finding was the correlation between tumor cell CD22 expression and treatment response, because seven of eight patients with unequivocal CD22 expression had objective responses, compared with only one of four patients with weak CD22 expression, whereas the single patient with an apparent CD22-negative tumor exhibited progressive disease. In contrast, the relationship between tumor radiation dose and response remains less clear. This may, in part, reflect the coadministration of unconjugated epratuzumab, which itself has biological activity; however, efficacy is usually obtained in clinical trials repeatedly administering epratuzumab at higher doses (360 mg/m 2 ) compared with the 1.5 mg/kg dosing used here. The 3.8 Gy median tumor dose with first infusion may be sufficient to induce complete responses if delivered by external beam radiotherapy (34) . However, although the estimated tumor radiation doses varied almost 10-fold, the difference between median tumor radiation doses for patients achieving complete responses, partial responses, or those without objective responses did not show an entirely consistent pattern.
The relevance of targeting/dosimetry in evaluating tumor response to radioimmunotherapy continues to be a matter of debate (35, 36) , reflecting not only limitations in the current methodology used for accurately determining tumor doses from planar images as well as the multifactorial nature of tumors, but also effects from the coadministration of cold antibody as has been directly investigated in a randomized trial, comparing response rates of cold and radiolabeled tositumomab with cold tositumomab alone (37) . The lack of clear relationship between dosimetry and response has further been raised in other radioimmunotherapy NHL studies using single dose administration of [ 90 Y]epratuzumab (27) . In this study of fractionated radioimmunotherapy, dosimetry estimates are further based only on 111 In imaging with the first infusion and a baseline computed tomography scan. For example, two patients had visible and palpable tumors that shrunk during the treatment period, and because absorbed tumor dose is inversely proportional to the tumor mass, the actual radiation dose delivered to their tumors might have been even higher (38, 39) . The observation that both patients with repeated tumor dosimetry each had retreatment values twice that of initial treatment indicates the potential usefulness of fractionation.
Whereas the addition of unconjugated antibody (cold monoclonal antibody) to radioimmunotherapy protocols presumably improves dose distribution by blocking unwanted sequestration of the radiolabeled antibody, the amount of cold monoclonal antibody is likely to have an optimum (40) above which the dose distribution is worsened. Cold epratuzumab blood levels increased on the day of second, third, and fourth infusions. This progressive rise in the circulating unconjugated antibodies might interfere with the binding of the radiolabeled antibody at the tumor site, raising the question of the suitability of using 1.5 mg/kg per infusion in this fractionated schedule. A lower amount of cold antibody has been advocated and used in single therapeutic infusion study using epratuzumab (27) . The finding that the absorbed tumor dose was lower following the third compared 
